Trastuzumab in adjuvant therapy for early-stage breast cancer

Steven J. Tucker, Matt Stenger, Edith A. Perez

Research output: Contribution to journalReview articlepeer-review


It was the topic that set ASCO on its ear: current trials now indicate that adding trastuzumab prolongs disease-free survival. The data are so strong, they warrant a change in the standard of care from adjuvant anthracycline therapy, with or without taxanes, to adjuvant treatment with trastuzumab for eligible patients with HER2+ resected breast cancer.

Original languageEnglish (US)
Pages (from-to)388-390+395
JournalCommunity Oncology
Issue number5
StatePublished - Jan 1 2005

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Trastuzumab in adjuvant therapy for early-stage breast cancer'. Together they form a unique fingerprint.

Cite this